Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Immune Design Corp.
Headquarters: Seattle, WA, United States of America
Website: N/A
Year Founded: 2008
Status: Acquired
BioCentury | Jun 14, 2022
Data Byte
Pipeline of 19 rare disease lentiviral therapies buoyed by bluebird vote
The clinical pipeline of lentivirus-based gene therapies for rare diseases contains at least 19 programs by 10 companies
BioCentury | Jan 20, 2022
Product Development
Moving beyond a 45-year-old antiviral for herpes
Improved antivirals, antibodies, vaccines and possible cures enter the horizon
BioCentury | Sep 11, 2021
Management Tracks
New CEO for Eden following conviction of JHL execs
Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more
BioCentury | Apr 18, 2020
Management Tracks
PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more
BioCentury | Feb 6, 2020
Deals
Beyond Keytruda: How Merck envisions innovation and growth after a spinout
Recent and future BD will help drive Merck's innovation, while slower-growing businesses are headed for a new entity
BioCentury | Oct 28, 2019
Finance
Nuvation Bio taking multimechanism approach with $275M series A
With a management team stocked with ex-Medivation execs, Nuvation aims to develop a broad oncology pipeline
BioCentury | Jul 13, 2019
Product Development
Why Merck is in infectious disease for the long haul
New commercial incentives could reward Merck for staying the course in infectious disease
BioCentury | Feb 22, 2019
Company News
Merck to expand cancer vaccine tech portfolio with Immune Design bid
BioCentury | Feb 21, 2019
Company News
Merck to expand cancer vaccine tech portfolio with Immune Design bid
Items per page:
1 - 10 of 91